Insights

The reading list.

Perspectives on financing high-cost pharmacy and medical therapies — specialty drug trends, cell & gene therapy economics, and the science and policy shaping them.

US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery

FDA approvals rebounded in 2023, raising hopes of a biotech recovery — and expanding the pipeline of high-cost advanced therapies payers must plan for.

Read →

Orchard sets out to sell world’s priciest gene therapy

A look at the market forces behind the world's most expensive gene therapy — and what record price tags mean for the payers who cover them.

Read →

First FDA-approved therapy utilizing CRISPR/Cas9 technology is approved for the treatment of sickle cell disease

The first CRISPR/Cas9 therapy wins FDA approval for sickle cell disease — a milestone in curative medicine, and in the cost of delivering it.

Read →

Bridging the Gap: Addressing the Financial Challenges of High-Cost Medical Therapies with PayRx

As medical science advances, we're seeing a surge in high-cost therapies — and PayRx is closing the gap between clinical breakthroughs and what payers can actually afford.

Read →

AstraZeneca strikes $1 billion deal for Pfizer rare-disease gene therapies

AstraZeneca's $1B move for Pfizer's rare-disease gene therapies signals how central advanced therapies have become to pharma strategy — and payer budgets.

Read →

Need more help?

Put these insights to work.

Learn how PayRx can help you and your customers address the challenge of high-cost pharmacy and medical therapies.